COVID-19 - Considerations for the paediatric rheumatologist
- PMID: 32283324
- PMCID: PMC7151358
- DOI: 10.1016/j.clim.2020.108420
COVID-19 - Considerations for the paediatric rheumatologist
Abstract
The novel coronavirus SARS-CoV2 is a threat to the health and well-being of millions of lifes across the globe. A significant proportion of adult patients require hospitalisation and may develop severe life-threatening complications. Children, on the other hand, can carry and transmit the virus, but usually do not develop severe disease. Mortality in the paediatric age-group is relatively low. Differences in virus containment and clearance, as well as reduced inflammation-related tissue and organ damage may be caused by age-specific environmental and host factors. Since severe complications in adults are frequently caused by uncontrolled immune responses and a resulting "cytokine storm" that may be controlled by targeted blockade of cytokines, previously established treatment with immunosuppressive treatments may indeed protect children from complications.
Keywords: ARDS; COVID; Cytokine storm; Inflammation; Paediatric; Rheumatology; SARS; SARS-CoV2.
Copyright © 2020. Published by Elsevier Inc.
References
-
- Henry B.M., Lippi G., Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin. Chem. Lab. Med. 2020:1–4. - PubMed
-
- Dong Y., Mo X., Hu Y. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous